Displaying drugs 651 - 675 of 11777 in total
Etilefrine
Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
Approved
Withdrawn
Matched Description: … It has been used as a vasoconstrictor agent. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Novobiocin
Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964...
Approved
Investigational
Vet approved
Withdrawn
Matched Description: … It has a chemical structure similar to coumarin. ... (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
Novobiocin sodium, a salt form …
Oteracil
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ... ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. ... It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy …
Lidoflazine
Approved
Experimental
Sulconazole
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Lennox-Gastuat syndrome, a form of childhood epilepsy. ... Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like …
Nomifensine
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … FDA published a notice of its determination that Merital capsules were removed from the market for safety …
Acetohexamide
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Description: … A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. …
Clodronic acid
Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid,...
Approved
Investigational
Vet approved
Matched Description: … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid] ... [A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification …
Mefenamic acid
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Approved
Matched Description: … A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties …
Etacrynic acid
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Matched Description: … This compound has been classified as a loop or high ceiling diuretic. ... A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of …
Insulin aspart
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening ... Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. ... Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type …
Abaloparatide
Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids...
Approved
Investigational
Matched Description: … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and …
Benzyl alcohol
Approved
Bempedoic acid
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are...
Approved
Investigational
Matched Description: … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. ... Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a ... A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased …
Bisoxatin
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions …
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in...
Approved
Matched Description: … A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection ... Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit …
Hexocyclium
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Cipaglucosidase alfa
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … a deficiency in GAA. ... Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. ... Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated …
Pamidronic acid
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Description: … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Displaying drugs 651 - 675 of 11777 in total